Searched for: in-biosketch:true
person:izmirp01
Neonatal Lupus: Clinical Spectrum, Biomarkers, Pathogenesis, and Approach to Treatment
Chapter by: Buyon, JP; Saxena, A; Izmirly, PM
in: Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects by
pp. 451-461
ISBN: 9780128020098
CID: 2169102
Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus
Saxena, Amit; Izmirly, Peter M; Han, Sung Won; Briassouli, Paraskevi; Rivera, Tania L; Zhong, Hua; Friedman, Deborah M; Clancy, Robert M; Buyon, Jill P
BACKGROUND: Cardiac manifestations of neonatal lupus (cardiac NL) include congenital heart block and cardiomyopathy. Several candidate biomarkers were evaluated in cases at risk for cardiac NL on the basis of potential roles in inflammation, fibrosis, and cardiac dysfunction: C-reactive protein (CRP); NT-pro-B-type natriuretic peptide (NT-proBNP); troponin I; matrix metalloproteinase (MMP)-2; urokinase plasminogen activator (uPA); urokinase plasminogen activator receptor (uPAR); plasminogen; and vitamin D. OBJECTIVES: Identification of maternal and fetal biomarkers associated with development and morbidity of cardiac NL should provide clues to pathogenesis with translational implications for management. METHODS: Cord (139) and maternal (135) blood samples collected during pregnancies at risk for cardiac NL were available for study. Levels of cord and maternal CRP, cord NT-proBNP, and cord troponin I were evaluated using multiplex assays. Cord and maternal vitamin D were assessed by liquid chromatography-mass spectrometry. MMP-2, uPA, uPAR, and plasminogen were evaluated using ELISA. RESULTS: Cord CRP, NT-proBNP, MMP-2, uPA, uPAR, and plasminogen levels were higher in cardiac NL-affected fetuses than in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL development, and medications taken during pregnancy. These biomarkers were positively associated with a disease severity score derived from known risk factors for mortality in cardiac NL. Maternal CRP and cord troponin I levels did not differ between the groups. Cord and maternal vitamin D levels were not significantly associated with cardiac NL, but average maternal vitamin D level during pregnancy was positively associated with longer time to postnatal pacemaker placement. CONCLUSIONS: These data support the association of fetal reactive inflammatory and fibrotic components with development and morbidity of cardiac NL. Following CRP and NT-proBNP levels after birth can potentially monitor severity and progression of cardiac NL. MMP-2 and the uPA/uPAR/plasminogen cascade provide therapeutic targets to decrease fibrosis. Although decreased vitamin D did not confer increased risk, given the positive influence on postnatal outcomes, maternal levels should be optimized.
PMCID:4545752
PMID: 26293764
ISSN: 1558-3597
CID: 1732472
TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus
Doerner, Jessica L; Wen, Jing; Xia, Yumin; Paz, Karin Blecher; Schairer, David; Wu, Lan; Chalmers, Samantha A; Izmirly, Peter; Michaelson, Jennifer S; Burkly, Linda C; Friedman, Adam J; Putterman, Chaim
Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK, TNFSF12) and its sole receptor Fn14, belonging to the TNF ligand and receptor superfamilies respectively, are involved in cell survival and cytokine production. The role of TWEAK/Fn14 interactions in the pathogenesis of cutaneous lupus has not been explored. TWEAK treatment of murine PAM212 keratinocytes stimulated the secretion of RANTES via Fn14 and promoted apoptosis. Parthenolide, but not wortmanin or the MAPK inhibitor PD98059, significantly decreased production of RANTES, indicating that this effect of TWEAK is mediated via NF-kappaB signaling. UVB irradiation significantly upregulated the expression of Fn14 on keratinocytes in vitro and in vivo and increased RANTES production. MRL/lpr Fn14 knockout (KO) lupus mice were compared with MRL/lpr Fn14 wild-type (WT) mice to evaluate for any possible differences in the severity of cutaneous lesions and the presence of infiltrating immune cells. MRL/lpr Fn14 KO mice had markedly attenuated cutaneous disease as compared with their Fn14 WT littermates, as evidenced by the well-maintained architecture of the skin and significantly decreased skin infiltration of T cells and macrophages. Our data strongly implicate TWEAK/Fn14 signaling in the pathogenesis of the cutaneous manifestations in the MRL/lpr model of spontaneous lupus and suggest a possible target for therapeutic intervention.
PMCID:4504782
PMID: 25826425
ISSN: 1523-1747
CID: 1669512
Serum biomarkers of inflammation, fibrosis, and cardiac function associate with diagnosis and severity of cardiac neonatal lupus [Meeting Abstract]
Saxena, A.; Izmirly, P. M.; Han, S.; Briassouli, P.; Rivera, T. L.; Zhong, H.; Friedman, D.; Clancy, R. M.; Buyon, J. P.
ISI:000360421900257
ISSN: 0392-856x
CID: 2961932
The clinical spectrum of autoimmune congenital heart block
Brito-Zeron, Pilar; Izmirly, Peter M; Ramos-Casals, Manuel; Buyon, Jill P; Khamashta, Munther A
Autoimmune congenital heart block (CHB) is an immune-mediated acquired disease that is associated with the placental transference of maternal antibodies specific for Ro and La autoantigens. The disease develops in a fetal heart without anatomical abnormalities that could otherwise explain the block, and which is usually diagnosed in utero, but also at birth or within the neonatal period. Autoantibody-mediated damage of fetal conduction tissues causes inflammation and fibrosis and leads to blockage of signal conduction at the atrioventricular (AV) node. Irreversible complete AV block is the principal cardiac manifestation of CHB, although some babies might develop other severe cardiac complications, such as endocardial fibroelastosis or valvular insufficiency, even in the absence of cardiac block. In this Review, we discuss the epidemiology, classification and management of women whose pregnancies are affected by autoimmune CHB, with a particular focus on the autoantibodies associated with autoimmune CHB and how we should test for these antibodies and diagnose this disease. Without confirmed effective preventive or therapeutic strategies and further research on the aetiopathogenic mechanisms, autoimmune CHB will remain a severe life-threatening disorder.
PMCID:5551504
PMID: 25800217
ISSN: 1759-4804
CID: 1513872
Rapid aneurysm growth and rupture in systemic lupus erythematosus
Graffeo, Christopher S; Tanweer, Omar; Nieves, Cesar Fors; Belmont, H Michael; Izmirly, Peter M; Becske, Tibor; Huang, Paul P
BACKGROUND: Subarachnoid hemorrhage (SAH) due to intracranial aneurysm rupture is a major neurosurgical emergency associated with significant morbidity and mortality. Rapid aneurysm growth is associated with rupture. Systemic lupus erythematosus (SLE) is a multi-system autoimmune disorder whose complications can include cerebral vasculitis and vasculopathy. Intracranial aneurysms are not known to occur more frequently in SLE patients than the general population; however, aneurysm growth rates have not been studied in SLE. CASE DESCRIPTION: We present a 43-year-old female with SLE on prednisone, hydroxychloroquine, and azathioprine with moderate disease activity who presented with severe, acute-onset headache and was found to have Hunt and Hess grade II SAH due to rupture of an 8 mm saccular anterior communicating artery (ACoA) aneurysm. The patient developed severe vasospasm, re-ruptured, and was taken for angiography and embolization, which was challenging due to a high degree of vasospasm and arterial stenosis. Review of imaging from less than 2 years prior demonstrated a normal ACoA complex without evidence of an aneurysm. CONCLUSION: We review the literature and discuss the risk factors and pathophysiology of rapid aneurysm growth and rupture, as well as the pathologic vascular changes associated with SLE. Although SLE patients do not develop intracranial aneurysm at an increased rate, these changes may predispose them to higher incidence of growth and rupture. This possibility-coupled with increased morbidity and mortality of SAH in SLE-suggests that SAH should be considered in SLE patients presenting with headache, and advocates for more aggressive treatment of SLE patients with unruptured aneurysms.
PMCID:4310132
PMID: 25657862
ISSN: 2152-7806
CID: 1456852
Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE [Meeting Abstract]
Blazer, Ashira; Markham, Andrew; Rasmussen, Sara; Buyon, Jill P; Belmont, HMichael; Mehta-Lee, Shilpi; Nwaukoni, Janet; Izmirly, Peter M; Clancy, Robert
ISI:000370860202074
ISSN: 2326-5205
CID: 2029542
Single-Cell RNA Sequencing of Human Podocytes, Endothelial Cells, and Tubular Cells Identifies Markers and Gene Profiles Differentiating Class IV and Class V Renal Disease in Lupus Nephritis [Meeting Abstract]
Der, Even; Akat, Kemal; Clancy, Robert; Goilav, Beatrice; Broder, Anna R; Belmont, HMichael; Izmirly, Peter M; Jordan, Nicole; Wang, Tao; Pullman, James; Schwartz, Daniel; Wu, Ming; Tuschl, Thomas; Buyon, Jill P; Putterman, Chaim
ISI:000370860202335
ISSN: 2326-5205
CID: 2029552
Single Cell Sequencing of Non-Lesional Non-Sun Exposed Skin from SLE Patients with Proteinuria Supports Widespread Endothelial Activation [Meeting Abstract]
Clancy, Robert; Der, Evan; Akat, Kemal; Broder, Anna R; Belmont, HMichael; Izmirly, Peter M; Goilav, Beatrice; Tuschl, Thomas; Putterman, Chaim; Buyon, Jill P
ISI:000370860202436
ISSN: 2326-5205
CID: 2029562
Long-Term Outcomes in Cardiac Neonatal Lupus and Associated Risk Factors for Morbidity [Meeting Abstract]
Saxena, Amit; Izmirly, Peter M; Sahl, Sara; Friedman, Deborah; Buyon, Jill P
ISI:000370860203452
ISSN: 2326-5205
CID: 2029582